<DOC>
	<DOCNO>NCT00061646</DOCNO>
	<brief_summary>The primary objective Phase II study ass safety , pharmacokinetics effectiveness ABT-510 combination standard carboplatin/paclitaxel chemotherapy subject stage IIIb IV NSCLC .</brief_summary>
	<brief_title>Safety Effectiveness ABT-510 Plus Combination Chemotherapy Subjects With Non-Small Cell Lung Cancer ( NSCLC )</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Inclusion Criteria The subject least 18 year age . The subject histologically cytology document Stage IIIB pleural effusion Stage IV NSCLC . The subject must measurable disease ( RECIST Criteria Tumor Response ) . The subject receive first line therapy treatment NSCLC . The subject must pregnant lactating subject ( male female ) must use contraceptive method deem acceptable investigator study two month follow completion therapy . The subject Eastern Cooperative Oncology Group ( ECOG ) performance score 01 . The subject able selfadminister caregiver reliably administer SC injection . The subject must adequate bone marrow , renal hepatic function follow : Bone marrow : White blood cell count ( WBC ) &gt; = 3,000/mm3 ; Platelets ; &gt; = 100,000/mm3 ; Hemoglobin &gt; = 9.0 g/dL ; Renal function : Serum creatinine &lt; = 2.0 mg/dL ; Hepatic function : Bilirubin &lt; = 1.5 mg/dL ; AST ALT &lt; = 1.5 X upper normal limit ( ULN ) ; unless liver metastasis present , AST ALT &lt; = 5.0 x ULN . The subject voluntarily sign date Institutional Review Board ( IRB ) /Independent Ethics Committee ( IEC ) approve consent prior study specific procedure . Exclusion Criteria The subject history currently exhibit Central Nervous System ( CNS ) metastasis . Brain MRI within 28 day enrollment require confirm absence CNS metastases . The subject receive therapeutic anticoagulation therapy . Low dose anticoagulation catheter prophylaxis permit ; PT/PTT must within normal limit . The subject history currently exhibit clinically significant cancer relate event bleed ( e.g. , hemoptysis ) . The subject recent history ( within 4 week Study Day 1 ) currently exhibit clinically significant event bleed . The subject receive investigational therapy within four week prior study drug administration . The subject exhibit evidence clinically significant uncontrolled condition ( ) and/or consider investigator unable tolerate propose treatment procedure . The subject previous current malignancy site , exception : Adequately treat situ carcinoma cervix uterus ; Basal squamous cell carcinoma skin ; Previous nonpulmonary malignancy confine surgically resect evidence active malignancy .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2007</verification_date>
	<keyword>Stage IIIb pleural effusion IV NSCLC</keyword>
</DOC>